Danaher (NYSE:DHR – Get Rating) had its price target cut by research analysts at Robert W. Baird from $334.00 to $319.00 in a research report issued to clients and investors on Friday, The Fly reports. Robert W. Baird’s price objective would suggest a potential upside of 14.65% from the stock’s previous close.
Other equities analysts have also recently issued research reports about the stock. Sanford C. Bernstein began coverage on shares of Danaher in a research note on Monday, January 10th. They set an “outperform” rating and a $365.00 target price on the stock. StockNews.com upgraded shares of Danaher from a “hold” rating to a “buy” rating in a research note on Thursday, March 24th. Barclays lowered their target price on shares of Danaher from $355.00 to $325.00 and set an “overweight” rating on the stock in a research note on Thursday, January 27th. Zacks Investment Research cut shares of Danaher from a “buy” rating to a “hold” rating and set a $295.00 target price on the stock. in a research note on Monday, January 31st. Finally, Wells Fargo & Company lowered their target price on shares of Danaher from $350.00 to $330.00 and set an “overweight” rating on the stock in a research note on Friday, January 28th. Two research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $332.20.
Shares of DHR stock opened at $278.24 on Friday. Danaher has a one year low of $238.32 and a one year high of $333.96. The company’s 50-day moving average is $278.96 and its 200 day moving average is $295.52. The company has a market capitalization of $199.04 billion, a price-to-earnings ratio of 32.28, a price-to-earnings-growth ratio of 1.30 and a beta of 0.78. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.09 and a current ratio of 1.43.
In other Danaher news, SVP Brian W. Ellis sold 5,365 shares of the stock in a transaction that occurred on Wednesday, February 2nd. The shares were sold at an average price of $293.99, for a total transaction of $1,577,256.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Joakim Weidemanis sold 20,508 shares of the stock in a transaction that occurred on Monday, January 31st. The shares were sold at an average price of $285.24, for a total transaction of $5,849,701.92. The disclosure for this sale can be found here. 11.20% of the stock is currently owned by company insiders.
Institutional investors and hedge funds have recently made changes to their positions in the business. Huntington National Bank grew its holdings in Danaher by 28.9% during the 4th quarter. Huntington National Bank now owns 182,155 shares of the conglomerate’s stock valued at $59,930,000 after buying an additional 40,857 shares in the last quarter. Teacher Retirement System of Texas grew its holdings in shares of Danaher by 30.5% in the third quarter. Teacher Retirement System of Texas now owns 207,094 shares of the conglomerate’s stock valued at $63,048,000 after purchasing an additional 48,378 shares in the last quarter. Illinois Municipal Retirement Fund grew its holdings in shares of Danaher by 23.1% in the fourth quarter. Illinois Municipal Retirement Fund now owns 12,791 shares of the conglomerate’s stock valued at $4,208,000 after purchasing an additional 2,401 shares in the last quarter. Hikari Power Ltd grew its holdings in shares of Danaher by 0.3% in the fourth quarter. Hikari Power Ltd now owns 190,870 shares of the conglomerate’s stock valued at $62,798,000 after purchasing an additional 580 shares in the last quarter. Finally, Geneos Wealth Management Inc. grew its holdings in shares of Danaher by 5.2% in the third quarter. Geneos Wealth Management Inc. now owns 14,005 shares of the conglomerate’s stock valued at $4,234,000 after purchasing an additional 697 shares in the last quarter. 82.84% of the stock is owned by institutional investors and hedge funds.
Danaher Company Profile (Get Rating)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy.
- Get a free copy of the StockNews.com research report on Danaher (DHR)
- Should You Buy Carvana or AutoNation or Pass on Both?
- MarketBeat Podcast: 3 Stocks Flashing Buy Signals
- What Should Investors Take Away From Boston Beer’s Earnings?
- High-Yield Kinder Morgan Is Still A Buy
- NextEra Energy Offers a Long-Term Gain if You Can Tolerate Short-Term Pain
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.